Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

doi:10.4254/wjh.v12.i12.1258

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5002)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

274

WORD

155

HTML

2399

Figures (1-2)

209

Tables (1-3)

190

Sum=3227

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

653

Download

1122

Sum=1775

Dec 27, 2020 (publication date) through Aug 1, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Dec 27, 2020; 12(12): 1258-1167
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1258

Full Size Figure Download Figure

Figure 1 Flow diagram for primary outcome (resolution of hepatic steatosis). PCSK9: Proprotein convertase subtilisin/kexin type-9.

Citation: Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167
URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1258